WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
US court rejects a request by tribes to block $10B energy transmission project in ArizonaCanton Fair opens in China with surge in overseas purchasersMadonna, 65, flashes her cleavage while leaning over a Bible with a man next to her as she covers ReWho will win the NHL's top awards this season? Here are AP's predictionsThe Taliban suspend two TV stations in Afghanistan for neglecting Islamic and national valuesThe wild TRUTH behind 'Mormon face': Former member of ultraParents of Bobby Maher, 14, watched helplessly as medics tried to save their sonPakistan targets right T20 combination against understrength New ZealandParents of Bobby Maher, 14, watched helplessly as medics tried to save their sonA storm dumps record rain across the desert nation of UAE and floods the Dubai airport
3.0641s , 4667.1171875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Watchers news portal